Carregant...
Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors
Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti‐PD1 agents), little is known about whether race‐ or sex‐based disparities exist in their use. In this observational study, we constructed a large and mostly community‐based cohort of patients with advanced s...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6291337/ https://ncbi.nlm.nih.gov/pubmed/30012876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0673 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|